My NCBISign In

Display Settings:

Format

Send to:

Choose Destination
    Clin Pharmacol Ther. 2012 Feb;91(2):189-200. doi: 10.1038/clpt.2011.245. Epub 2011 Dec 28.

    Pathways to drug development for autism spectrum disorders.

    Hampson DR, Gholizadeh S, Pacey LK.

    Source

    Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.

    Abstract

    Autism spectrum disorders (ASDs) are neurodevelopmental disorders whose prevalence has risen over the past two decades. Current drug treatments for ASDs and the related disorders-fragile X syndrome (FXS) and Rett syndrome-target specific symptoms but do not address the basic underlying etiologies. However, based partly on an improved understanding of the neurochemical underpinnings of FXS, pharmacotherapy for this syndrome has progressed to the point of clinical trials of several novel drug treatments. By contrast, our overall understanding of the neuropathophysiology of ASDs is still rudimentary. There is hope in the field that knowledge and experience gained in the study of fragile X and Rett syndromes may be applicable to the larger autism patient population. In this review, we discuss how recent advances in our understanding of the biochemistry and neuropathology of these disorders could lead to new more effective treatments for ASDs.

    PMID:
    22205199
    [PubMed - in process]

    LinkOut - more resources

    Full Text Sources

      Supplemental Content

      Click here to read

      Related citations

      See reviews... See all...

      Recent activity

      Clear Turn Off Turn On

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      You are here: NCBI > Literature > PubMed
      Write to the Help Desk